OverviewSuggest Edit

Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. Bicycle technology is based on discoveries made at the MRC Laboratory of Molecular Biology in Cambridge by co-founders, Professor Christian Heinis and Sir Gregory Winter, which have been developed at the company into a robust technology platform under the leadership of Dr. John Tite (CSO). 
TypePublic
HQBabraham, GB
Websitebicycletherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)67(+10%)
Job Openings6
Revenue (FY, 2020)$10.4 M(-24%)
Share Price (Jul 2021)$34.8
Cybersecurity ratingAMore

Key People/Management at Bicycle Therapeutics

Kevin Lee

Kevin Lee

CEO, Director
Lee Kalowski

Lee Kalowski

President and Chief Financial Officer
Nick Keen

Nick Keen

Chief Scientific Officer
Greg Winter

Greg Winter

Co-Founder, Director, Advisor
Michael Skynner

Michael Skynner

COO
Zafar Qadir

Zafar Qadir

General Counsel
Show more

Bicycle Therapeutics Office Locations

Bicycle Therapeutics has offices in Babraham and Lexington
Babraham, GB (HQ)
Meditrina Building, Babraham Research Campus
Lexington, MA, US
Hartwell Pl
Show all (2)

Bicycle Therapeutics Financials and Metrics

Bicycle Therapeutics Revenue

Bicycle Therapeutics's revenue was reported to be $10.39 m in FY, 2020
USD

Revenue (Q1, 2021)

1.8m

Net income (Q1, 2021)

(16.2m)

EBIT (Q1, 2021)

(16.0m)

Market capitalization (21-Jul-2021)

846.1m

Closing stock price (21-Jul-2021)

34.8

Cash (31-Mar-2021)

195.9m

EV

682.7m
Bicycle Therapeutics's current market capitalization is $846.1 m.
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

836.1k81.1k45.0k2.1m7.1m13.8m10.4m

Revenue growth, %

246%

General and administrative expense

6.4m8.1m14.6m29.2m

R&D expense

11.9m70.8m25.5m33.1m
Quarterly
USDQ2, 2019Q3, 2019Q2, 2020Q3, 2020Q1, 2021

Revenue

1.5m614.0k1.6m3.8m1.8m

General and administrative expense

3.0m4.8m6.2m7.2m8.1m

R&D expense

6.5m6.1m8.0m7.4m9.7m

Operating expense total

9.5m10.9m14.2m14.5m17.8m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

2.3m451.3k5.4m6.5m67.7m63.4m

Accounts Receivable

5.0m201.0k5.5m

Prepaid Expenses

848.0k2.1m4.9m5.1m

Current Assets

2.7m989.3k6.2m8.3m71.5m76.8m104.1m155.7m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

108.5m96.0m195.9m

Accounts Receivable

160.0k46.0k1.0m489.0k2.8m2.0m

Prepaid Expenses

2.0m3.5m4.2m4.3m5.5m6.0m

Current Assets

120.5m110.3m123.4m112.5m164.2m215.4m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(2.1m)(1.7m)(2.9m)(6.7m)(16.3m)(21.8m)(30.6m)(51.0m)

Depreciation and Amortization

332.0k712.0k960.0k1.3m

Accounts Payable

67.0k(169.0k)220.0k(663.0k)

Cash From Operating Activities

(1.4m)(26.1m)(28.6m)(17.8m)
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(16.7m)(26.2m)(11.3m)(23.4m)(33.6m)(16.2m)

Depreciation and Amortization

443.0k686.0k305.0k615.0k944.0k325.0k

Accounts Payable

530.0k516.0k2.7m1.3m193.0k(304.0k)

Cash From Operating Activities

(12.8m)(23.7m)21.2m8.8m(1.2m)(13.7m)
USDFY, 2013

Financial Leverage

1.1 x
Show all financial metrics

Bicycle Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
BicycleRD Limited
Bicycle Therapeutics Inc
BicycleTx Limited

Bicycle Therapeutics Revenue Breakdown

Embed Graph

Bicycle Therapeutics revenue breakdown by business segment: 24.4% from Oxurion Agreement, 56.2% from Bioverativ Agreement and 19.4% from AstraZeneca Agreement

Bicycle Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Bicycle Therapeutics Online and Social Media Presence

Embed Graph

Bicycle Therapeutics News and Updates

Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology

CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated...

Steven Cohen Shifts Into A Higher Gear With Bicycle Therapeutics

Guru's firm increases stake in clinical-stage biotech

Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment

Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision. The company said the Phase 1 trial …

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million

Bicycle Therapeutics plc priced its initial public offering late Wednesday at $14 per American Depositary Share, selling 4.3 million shares to raise $60.2 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BCYC." Separately, Ideaya Biosciences priced its IPo at…

Bicycle Therapeutics Blogs

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics

Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics Content Import Tue, 07/13/2021 - 07:00 Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleot…

Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021

Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021 Content Import Tue, 06/15/2021 - 16:31 Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021 …

Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

- BT7480, the lead Bicycle tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 “New Drugs on the Horizon” session; remains on-track for 2H'21 clinical trial start - Achieved significant recent progress across pipeline of Bicycle ®-based therapies beyond oncology - Raised $75.0

Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021

- BT7480 to be presented in a “New Drugs on the Horizon” session; on-track to enter the clinic in 2H’21 CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Apr. 10, 2021-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based …

Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology

Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology Content Import Tue, 03/30/2021 - 07:01 Bicycle Therapeutics Announces Significant Progress Across Multiple Therapeutic Programs Beyond Oncology March 30, 2021 at 7:00 AM …

Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors

Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors Content Import Thu, 03/18/2021 - 08:34 Bicycle Therapeutics Appoints Jose-Carlos Gutierrez-Ramos, Ph.D., to its Board of Directors March 18, 2021 at 8:34 AM EDT This re…
Show more

Bicycle Therapeutics Frequently Asked Questions

  • Who are Bicycle Therapeutics key executives?

    Bicycle Therapeutics's key executives are Kevin Lee, Lee Kalowski and Nick Keen.

  • How many employees does Bicycle Therapeutics have?

    Bicycle Therapeutics has 67 employees.

  • What is Bicycle Therapeutics revenue?

    Latest Bicycle Therapeutics annual revenue is $10.4 m.

  • What is Bicycle Therapeutics revenue per employee?

    Latest Bicycle Therapeutics revenue per employee is $155.1 k.

  • Who are Bicycle Therapeutics competitors?

    Competitors of Bicycle Therapeutics include Centivax, Confo Therapeutics and Sigilon.

  • Where is Bicycle Therapeutics headquarters?

    Bicycle Therapeutics headquarters is located at Meditrina Building, Babraham Research Campus, Babraham.

  • Where are Bicycle Therapeutics offices?

    Bicycle Therapeutics has offices in Babraham and Lexington.

  • How many offices does Bicycle Therapeutics have?

    Bicycle Therapeutics has 2 offices.